Q2 2026 saw a transformative out-licensing deal for Idefirix in Europe, strong clinical data, and robust U.S. launch preparations. Revenue was SEK 48.1 million, with a strengthened balance sheet from the SERB upfront payment. U.S. launch readiness and further collaborations remain key priorities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.